Benzinga | Aug 12, 2021 04:51AM EDT

SVB Leerink Downgrades Intersect ENT to Market Perform, Announces $28.25 Price Target

SVB Leerink analyst Richard Newitter downgrades Intersect ENT (NASDAQ:XENT) from Outperform to Market Perform and announces $28.25 price target.